Evidence map›Paper›PMID 29955851›Full record

ArticleJournal of public health (Oxford, England)2019

Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness.

Sudhir Venkatesan, Cristina Carias, Matthew Biggerstaff, Angela P Campbell, Jonathan S Nguyen-Van-Tam, Emily Kahn, Puja R Myles, Martin I Meltzer

Abstract read
In one paragraph

Article in Journal of public health (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sudhir VenkatesanDivision of Epidemiology and Public Health, University of Nottingham, Nottingham, UK.
Cristina CariasCenters for Disease Control and Prevention, Atlanta, GA, USA.
Matthew BiggerstaffCenters for Disease Control and Prevention, Atlanta, GA, USA.
Angela P CampbellCenters for Disease Control and Prevention, Atlanta, GA, USA.
Jonathan S Nguyen-Van-TamDivision of Epidemiology and Public Health, University of Nottingham, Nottingham, UK.
Emily KahnCenters for Disease Control and Prevention, Atlanta, GA, USA.
Puja R MylesDivision of Epidemiology and Public Health, University of Nottingham, Nottingham, UK.
Martin I MeltzerCenters for Disease Control and Prevention, Atlanta, GA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany countries have acquired antiviral stockpiles for pandemic influenza mitigation and a significant part of the stockpile may be focussed towards community-based treatment.

methodsWe developed a spreadsheet-based, decision tree model to assess outcomes averted and cost-effectiveness of antiviral treatment for outpatient use from the perspective of the healthcare payer in the UK. We defined five pandemic scenarios-one based on the 2009 A(H1N1) pandemic and four hypothetical scenarios varying in measures of transmissibility and severity.

resultsCommunity-based antiviral treatment was estimated to avert 14-23% of hospitalizations in an overall population of 62.28 million. Higher proportions of averted outcomes were seen in patients with high-risk conditions, when compared to non-high-risk patients. We found that antiviral treatment was cost-saving across pandemic scenarios for high-risk population groups, and cost-saving for the overall population in higher severity influenza pandemics. Antiviral effectiveness had the greatest influence on both the number of hospitalizations averted and on cost-effectiveness.

conclusionsThis analysis shows that across pandemic scenarios, antiviral treatment can be cost-saving for population groups at high risk of influenza-related complications.

Indexed as

Decision TreesPandemicsAmbulatory CareAntiviral AgentsCost-Benefit AnalysisHospitalizationHumansInfluenza A Virus, H1N1 SubtypeInfluenza, HumanSeverity of Illness IndexTreatment OutcomeUnited KingdomAntiviral Agentscost-effectivenessdecision treeneuraminidase inhibitorspandemic influenza

Identifiers

PMID29955851
PMCPMC7313872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.